- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.01. | B.Riley initiates coverage on Aardvark Therapeutics stock with Buy rating | 4 | Investing.com | ||
| 28.01. | B.Riley nimmt Aardvark Therapeutics mit Kaufempfehlung in die Bewertung auf | 3 | Investing.com Deutsch | ||
| 12.01. | Aardvark Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.01. | Raymond James bestätigt "Strong Buy" für Aardvark Therapeutics mit Kursziel von 47 Dollar | 4 | Investing.com Deutsch | ||
| 12.01. | Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target | 3 | Investing.com | ||
| 23.12.25 | Oppenheimer initiates Aardvark Therapeutics stock with Outperform rating | 2 | Investing.com | ||
| 23.12.25 | Oppenheimer startet Coverage für Aardvark Therapeutics mit "Outperform" | 3 | Investing.com Deutsch | ||
| 12.12.25 | William Blair initiates coverage on Aardvark Therapeutics stock with Outperform rating | 1 | Investing.com | ||
| AARDVARK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.12.25 | William Blair nimmt Coverage für Aardvark Therapeutics mit "Outperform" auf | 4 | Investing.com Deutsch | ||
| 11.12.25 | Aardvark Therapeutics stock rises 13% on positive trial updates, BTIG maintains Buy | 1 | Investing.com | ||
| 11.12.25 | Raymond James bestätigt Aardvark Therapeutics mit "Strong Buy" und Kursziel von 47 $ | 3 | Investing.com Deutsch | ||
| 11.12.25 | Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target | 4 | Investing.com | ||
| 10.12.25 | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome | 185 | GlobeNewswire (Europe) | Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout Clinical trial sites in Canada and the United Kingdom have received regulatory clearance... ► Artikel lesen | |
| 10.12.25 | Aardvark Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.12.25 | Raymond James startet Coverage für Aardvark Therapeutics mit "Strong Buy" und hohem Kurspotenzial | 5 | Investing.com Deutsch | ||
| 02.12.25 | Raymond James initiates coverage on Aardvark Therapeutics stock with Strong Buy | 3 | Investing.com | ||
| 14.11.25 | Stifel reiterates Buy rating on Aardvark Therapeutics stock, maintains $24 target | 1 | Investing.com | ||
| 14.11.25 | Aardvark Therapeutics stock price target lowered to $18 at RBC Capital | 2 | Investing.com | ||
| 13.11.25 | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates | 290 | GlobeNewswire (Europe) | Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associated... ► Artikel lesen | |
| 13.11.25 | Aardvark Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOCRYST PHARMACEUTICALS | 5,392 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 | ||
| MICROBOT MEDICAL | 1,475 | -1,80 % | Microbot Medical Inc. - 8-K, Current Report | ||
| IMMUNITYBIO | 5,118 | +0,08 % | ImmunityBio launches phase 2 trial for chemotherapy-free lymphoma therapy | ||
| VOYAGER THERAPEUTICS | 3,126 | +0,51 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2025 Financial and Operating Results | - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle discovery... ► Artikel lesen | |
| CAPRICOR | 19,000 | -9,31 % | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data | FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO,... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 4,280 | -1,38 % | Abeona Therapeutics Inc.: Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer | CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,200 | -1,37 % | Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 | ||
| VIR BIOTECHNOLOGY | 7,180 | +3,76 % | EQS-News: Norgine Pharmaceuticals Limited: Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology | EQS-News: Norgine Pharmaceuticals Limited
/ Schlagwort(e): Produkteinführung/Vereinbarung
Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 65,00 | -7,14 % | Palvella Therapeutics: Clear Street bestätigt Kaufempfehlung im Vorfeld von Studiendaten | ||
| DBV TECHNOLOGIES | 3,520 | -3,43 % | DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 | Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 12,200 | -3,17 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted six newly-hired employees inducement options to purchase an... ► Artikel lesen | |
| MARKER THERAPEUTICS | 1,260 | -9,35 % | Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 5,500 | +0,92 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants | ||
| ALIGOS THERAPEUTICS | 5,400 | -12,90 % | Aligos Therapeutics, Inc. - 8-K, Current Report | ||
| QUANTUM-SI | 1,060 | +13,72 % | Quantum-Si Inc - 8-K, Current Report |
Das Unternehmen AARDVARK THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 12,725 Euro und damit +12,71 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AARDVARK THERAPEUTICS INC finden Sie auf Wallstreet Online.